Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×SSRI (selective serotonin reuptake inhibitor)

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs name citalopram among the selective serotonin reuptake inhibitors (SSRIs) that can potentiate its anticoagulant effect (acenocoumarol SmPCs, AEMPS). SSRIs raise the risk of bleeding on their own, and anticoagulants may add to this risk (citalopram SmPC, AEMPS; citalopram prescribing information, US Food and Drug Administration, FDA). Citalopram hardly inhibits liver enzymes. Its effect on CYP2C9 is negligible, and its effect on CYP1A2 and CYP2C19, which take part in the metabolism of R-acenocoumarol, is weak. With warfarin, there were no changes or only very small changes of no clinical importance (citalopram and acenocoumarol SmPCs, AEMPS). The documents contain no study with acenocoumarol. Citalopram 40 mg a day for 21 days did not change warfarin pharmacokinetics but raised the prothrombin time by 5%. The clinical significance of this is unknown (citalopram prescribing information, FDA).

Symptoms

The main risk is bleeding. With selective serotonin reuptake inhibitors (SSRIs), altered skin bleeding time and bleeding events have been described, such as bruising, gynaecological and gastrointestinal bleeding and other skin or mucosal bleeding (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, such events range from bruising, haematomas, nosebleeds and petechiae to life-threatening bleeding (citalopram prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) name citalopram among the drugs that can potentiate its effect. They ask for close and frequent coagulation checks, for example twice a week. This applies both when such a drug is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Use citalopram with caution in patients on anticoagulants and in those with a history of bleeding disorders (citalopram SmPC, AEMPS). The US label says to inform patients of the increased risk of bleeding and, in patients taking warfarin, to monitor the international normalised ratio (INR) carefully (citalopram prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. After the bleeding, restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Citalopram